News Release 2017
-
- December 19, 2017
- Consolidation of Group Production Functions (Absorption-type Demerger and Absorption-type Merger among the Wholly Owned Subsidiaries of the Company)
-
- November 22, 2017
- Notice on Production and Marketing License Agreement with Vietnamese Pharmaceutical Company
-
- November 6, 2017
- Supplementary information (Nov 6, 2017)
-
- November 6, 2017
- Summary of Consolidated Financial Results(For the Second Quarter Ended September 30, 2017) [Japanese Standard]
-
- September 28, 2017
- Establishment of a Subsidiary
-
- July 31, 2017
- Summary of Consolidated Financial Results (For the first Quarter Ended Jun 30,2017)［Japanese Standard］
-
- July 31, 2017
- Consolidated Financial Results (For the first Quarter Ended Jun 30,2017)- Supplementary Information
-
- May 11, 2017
- Summary of Consolidated Financial Results
-
- May 11, 2017
- Consolidation of Group Production Functions
-
- April 11, 2017
- Kyorin acquired licenses from Merck & Co., Inc., Kenilworth, N.J., U.S.A. for Investigational Therapy for Overactive Bladder (Code:KRP-114V) in Asia
-
- February 22, 2017
- Change of Representative Director and President at ActivX Biosciences, Inc.
-
- February 22, 2017
- Establishment of a Representative Office in the Republic of Indonesia
-
- February 3, 2017
- Summary of Consolidated Financial Results (For the third Quarter Ended Dec 31,2016)［Japanese Standard］
-
- February 3, 2017
- Revision of Consolidated Financial Forecasts
-
- February 3, 2017
- Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2017
-
- January 11, 2017
- Conclusion of Agreement on Business Alliance for Sale of Hand-Sanitizers
